Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.

She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on 

Videos

Tiago Biachi, MD, PhD, highlighted the transformative role of personalized medicine in gastrointestinal (GI) cancer treatment through advances in next-generation sequencing and circulating tumor DNA, while emphasizing the importance of lifestyle factors in prevention and recurrence.






Personalized Medicine in GI Cancer: Transforming Treatment With Technology, Lifestyle Insights

Articles

Secukinumab delivers sustained efficacy and quality of life improvements in pediatric generalized pustular psoriasis (GPP). 

Secukinumab Shows Long-Term Efficacy, Safety in Pediatric GPP Treatment

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

Early onset active inflammatory bowel disease (IBD) is associated with significantly higher rates of psychiatric disorders and increased use of psychotropic medications.

Early Onset Active IBD Linked to Higher Rates of Psychiatric Disorders, Medication Use

Cameron Santoro is an associate editor for 

), AJMC.com, and The Center for Biosimilars

Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for patients, especially those who experience loss of response.

Hidradenitis Suppurativa: Advancing Treatment With Biologics

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Enhancing Patient Care in DLBCL and FL:  Insights on Industry-Provided Patient Support Services 

Video Series

Panelists discuss how they assess the individual support needs of patients diagnosed with diffuse large B-cell lymphoma or follicular lymphoma and describe an ideal model for industry-provided support services for these patients.

Tailored Support: The Role of Industry-Provided Services in Lymphoma Care

Video content above is prompted by the following:

How do you assess the individual support needs of each patient when they are diagnosed with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL)?

In a perfect world, describe what industry-provided support services look like for patients diagnosed with DLBCL and FL.

Panelists discuss how industry-provided patient support services can address the physical, emotional, and practical challenges faced by patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), from diagnosis through treatment and beyond.

Panelists discuss how a diagnosis of diffuse large B-cell lymphoma or follicular lymphoma affects patients physically and emotionally and how these challenges shape their treatment journey and overall care.

Challenges at Diagnosis: Navigating the Emotional and Physical Realities of DLBCL and FL

Panelists discuss the key challenges faced by patients with diffuse large B-cell lymphoma and follicular lymphoma at diagnosis, how these challenges evolve during treatment, and the emotional and psychological support strategies employed to help patients navigate their lymphoma journey.

Empowering Patients: Strategies for Emotional Resilience and Support in Lymphoma Care

Tailored Support: The Role of Industry-Provided Services in Lymphoma Care

EP: 1.Challenges at Diagnosis: Navigating the Emotional and Physical Realities of DLBCL and FL

EP: 2.Empowering Patients: Strategies for Emotional Resilience and Support in Lymphoma Care

EP: 3.Tailored Support: The Role of Industry-Provided Services in Lymphoma Care